ACVR1 Gene Fibrodysplasia ossificans progressiva Genetic Test
Test Details
The ACVR1 gene is responsible for encoding a protein called activin A receptor type 1 (ACVR1). Mutations in this gene are associated with a rare genetic disorder called fibrodysplasia ossificans progressiva (FOP).
Fibrodysplasia ossificans progressiva is characterized by the abnormal formation of bone in muscles, tendons, and ligaments. This leads to progressive restriction of movement and eventual immobilization of affected joints. The condition is typically diagnosed in early childhood and worsens over time.
NGS (next-generation sequencing) genetic testing is a method used to analyze an individual’s DNA to identify mutations or variations in specific genes. In the case of fibrodysplasia ossificans progressiva, NGS genetic testing can be used to identify mutations in the ACVR1 gene that are associated with the condition.
This type of genetic testing can help confirm a diagnosis of fibrodysplasia ossificans progressiva in individuals who exhibit symptoms of the disorder. It can also be used for carrier testing in individuals with a family history of the condition, as well as for prenatal testing in families at risk of having a child with fibrodysplasia ossificans progressiva.
Overall, NGS genetic testing for the ACVR1 gene in fibrodysplasia ossificans progressiva can provide important information for diagnosis, genetic counseling, and family planning.
Test Name: ACVR1 Gene Fibrodysplasia ossificans progressiva Genetic Test
Components:
- Price: 4400.0 AED
- Sample Condition: Blood
- Report Delivery: 3 to 4 Weeks
- Method: NGS Technology
- Test type: Osteology Dermatology Immunology Disorders
- Doctor: Dermatologist
- Test Department: Genetics
Pre Test Information:
Clinical History of Patient who is going for ACVR1 Gene Fibrodysplasia ossificans progressiva NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with ACVR1 Gene Fibrodysplasia ossificans progressiva NGS Genetic DNA Test gene ACVR1.
| Test Name | ACVR1 Gene Fibrodysplasia ossificans progressiva Genetic Test |
|---|---|
| Components | |
| Price | 4400.0 AED |
| Sample Condition | Blood |
| Report Delivery | 3 to 4 Weeks |
| Method | NGS Technology |
| Test type | Osteology Dermatology Immunology Disorders |
| Doctor | Dermatologist |
| Test Department: | Genetics |
| Pre Test Information | Clinical History of Patient who is going for ACVR1 Gene Fibrodysplasia ossificans progressiva NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with ACVR1 Gene Fibrodysplasia ossificans progressiva NGS Genetic DNA Test gene ACVR1 |
| Test Details | The ACVR1 gene is responsible for encoding a protein called activin A receptor type 1 (ACVR1). Mutations in this gene are associated with a rare genetic disorder called fibrodysplasia ossificans progressiva (FOP). Fibrodysplasia ossificans progressiva is characterized by the abnormal formation of bone in muscles, tendons, and ligaments. This leads to progressive restriction of movement and eventual immobilization of affected joints. The condition is typically diagnosed in early childhood and worsens over time. NGS (next-generation sequencing) genetic testing is a method used to analyze an individual’s DNA to identify mutations or variations in specific genes. In the case of fibrodysplasia ossificans progressiva, NGS genetic testing can be used to identify mutations in the ACVR1 gene that are associated with the condition. This type of genetic testing can help confirm a diagnosis of fibrodysplasia ossificans progressiva in individuals who exhibit symptoms of the disorder. It can also be used for carrier testing in individuals with a family history of the condition, as well as for prenatal testing in families at risk of having a child with fibrodysplasia ossificans progressiva. Overall, NGS genetic testing for the ACVR1 gene in fibrodysplasia ossificans progressiva can provide important information for diagnosis, genetic counseling, and family planning. |
